Wisdom Bioscience, a biotechnology company pioneering non-invasive diagnostics for oral cancer, has announced the formation of its Scientific Advisory Board (SAB) following the close of its initial funding round.
The board comprises leading experts in cell-free DNA (cfDNA), oncology screening and molecular diagnostics across research, development and commercialisation: Dr Giulia Kennedy, Dr Arnold Levine, Dr John Sninsky, Dr Martin Goldberg and Prof Tin Tin Su. The members will provide strategic scientific and clinical guidance as the company advances its product pipeline and expands its service offerings.
Dr Kennedy is co-founder and chief scientific officer of PinkDx, a molecular diagnostics company focused on gynaecological cancers in women. Prior to co-founding PinkDx, she served as chief scientific officer and chief medical officer at Veracyte, where she led the development and commercialisation of eight genomic diagnostic tests that transformed standards of patient care.
Dr Levine has spent more than 35 years conducting research in molecular oncology, genomics, tumour suppressor gene function and the epidemiological factors contributing to cancer development. More recently, his work has focused on immune responses to cancer, cancer therapies and prevention.
Dr Sninsky brings extensive leadership experience from senior management roles in both emerging and established laboratory-developed test and in vitro diagnostic organisations. His work has centred on translating scientific innovation into reimbursed clinical practice across infectious diseases, genetic conditions, oncology and solid organ transplantation. His technological expertise includes the development and commercialisation of polymerase chain reaction (PCR), next-generation sequencing (NGS) of the human genome, genome-wide association studies and liquid biopsy technologies.
Dr Goldberg currently serves as distinguished scientific fellow at Seer. He has more than 30 years of experience in the life sciences tools industry, spanning research-use and diagnostic platforms in genomics and proteomics. His work often focuses on the intersection of technical, operational and strategic challenges, particularly supporting early-stage biotechnology start-ups as they navigate growth and development.
Prof Su brings more than 25 years of expertise in chemical genetics and tissue regeneration following radiation damage, using both Drosophila and human cancer models in her research.
Founded in 2024, Wisdom Bioscience aims to transform oral cancer screening by integrating advanced genomic technologies into routine dental care. The company has developed a platform for the non-invasive detection of oral cancer, with the goal of introducing a screening test that can be performed during standard dental appointments.
Using a simple mouth swab combined with next-generation sequencing technology, the test is designed to enable earlier detection of oral cancer within an accessible clinical setting.
Wisdom Bioscience is backed by a distinguished group of investors, including Stephen Quake and Jay Flatley, providing strong validation of the company’s technology and commercial vision. Proceeds from the recent financing round will support continued clinical validation and preparations for a commercial launch later this year.
